Details for Patent: 12,678,442
Which drugs does patent 12,678,442 protect, and when does it expire?
Patent 12,678,442 protects JENTADUETO XR, JENTADUETO, and TRIJARDY XR, and is included in three NDAs.
Protection for TRIJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-nine patent family members in twenty-eight countries.
Summary for Patent: 12,678,442
| Title: | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| Abstract: | The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. |
| Inventor(s): | Thomas Friedl, Michael Braun, Kenji Egusa, Hikaru Fujita, Megumi Maruyama, Takaaki Nishioka |
| Assignee: | Boehringer Ingelheim International GmbH |
| Application Number: | US18/666,901 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 12,678,442
International Family Members for US Patent 12,678,442
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071175 | ⤷ Start Trial | |||
| Australia | 2009232043 | ⤷ Start Trial | |||
| Brazil | PI0911273 | ⤷ Start Trial | |||
| Canada | 2720450 | ⤷ Start Trial | |||
| Chile | 2009000809 | ⤷ Start Trial | |||
| China | 101983073 | ⤷ Start Trial | |||
| China | 103083672 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
